Maven Income & Growth VCT (MIG1) Competitors

Maven Income & Growth VCT (LON:MIG1) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations.

Does the media prefer MIG1 or IBT?

In the previous week, International Biotechnology had 3 more articles in the media than Maven Income & Growth VCT. MarketBeat recorded 4 mentions for International Biotechnology and 1 mentions for Maven Income & Growth VCT. Maven Income & Growth VCT's average media sentiment score of 1.83 beat International Biotechnology's score of 1.37 indicating that Maven Income & Growth VCT is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maven Income & Growth VCT	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
International Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is MIG1 or IBT a better dividend stock?

Maven Income & Growth VCT pays an annual dividend of GBX 2 per share and has a dividend yield of 5.4%. International Biotechnology pays an annual dividend of GBX 29 per share and has a dividend yield of 4.0%. Maven Income & Growth VCT pays out 99.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. International Biotechnology pays out 27.7% of its earnings in the form of a dividend.

Does the MarketBeat Community favor MIG1 or IBT?

International Biotechnology received 69 more outperform votes than Maven Income & Growth VCT when rated by MarketBeat users. Likewise, 77.71% of users gave International Biotechnology an outperform vote while only 67.00% of users gave Maven Income & Growth VCT an outperform vote.

Company	Underperform	Outperform
Maven Income & Growth VCT	Outperform Votes 67 67.00%	Underperform Votes 33 33.00%
International Biotechnology	Outperform Votes 136 77.71%	Underperform Votes 39 22.29%

Which has more volatility and risk, MIG1 or IBT?

Maven Income & Growth VCT has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, International Biotechnology has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.

Which has better valuation and earnings, MIG1 or IBT?

International Biotechnology has higher revenue and earnings than Maven Income & Growth VCT. International Biotechnology is trading at a lower price-to-earnings ratio than Maven Income & Growth VCT, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maven Income & Growth VCT	£5.32M	11.91	£3.55M	£2.02	18.32
International Biotechnology	£41.82M	6.19	£37.91M	£104.80	6.87

Is MIG1 or IBT more profitable?

International Biotechnology has a net margin of 90.66% compared to Maven Income & Growth VCT's net margin of 66.74%. International Biotechnology's return on equity of 13.67% beat Maven Income & Growth VCT's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maven Income & Growth VCT	66.74%	5.26%	-2.24%
International Biotechnology	90.66%	13.67%	3.57%

Do institutionals and insiders have more ownership in MIG1 or IBT?

45.2% of International Biotechnology shares are owned by institutional investors. 0.4% of Maven Income & Growth VCT shares are owned by company insiders. Comparatively, 4.2% of International Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

International Biotechnology beats Maven Income & Growth VCT on 13 of the 17 factors compared between the two stocks.